Zurueck zur Suche

Reporte zur Charge U95H7

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

5Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
CO 5

VAERS 1974419

GLAXOSMITHKLINE BIOLOGICALS · HEP A (HAVRIX) · Charge U95H7

gering
Staat
CO
Alter
0,8
Geschlecht
M
Eingang
23.12.2021
Impfdatum
12.09.2021
Beginn
12.09.2021
Tage bis Beginn
0,0
Dosis
3
Route/Site
- / LL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Extra dose administered Incorrect dose administered Product administered to patient of inappropriate age

Symptomtext

This case was reported by a physician via call center representative and described the occurrence of overdose in a 9-month-old male patient who received HAV (Havrix adult) (batch number U95H7, expiry date 22nd May 2022) for prophylaxis. Co-suspect products included HAV (Havrix adult) (batch number U95H7, expiry date unknown) for prophylaxis. Previously administered products included Havrix (received first dose on unknown date). On 12th September 2021, the patient received the 3rd dose of Havrix adult. On an unknown date, the patient received the 2nd dose of Havrix adult. On 12th September 2021, unknown after receiving Havrix adult and not applicable after receiving Havrix adult, the patient experienced overdose, adult product administered to child and extra dose administered. On an unknown date, the patient experienced adult product administered to child and overdose. On an unknown date, the outcome of the overdose, adult product administered to child, extra dose administered, adult product administered to child and overdose were unknown. Additional details were provided as follows: The pharmacist reported that patient received the adult dose of the Havrix vaccine inadvertently for their second and third dose of the series. The patients were administered the third dose of the vaccine series, which led to overdose, adult product administered to child, extra dose administered. The batch number was for second and third dose of Havrix vaccine was same. The reporter consented to follow up. The case has been linked to US2021254948 and US2021254932, reported by the same reporter.; Sender's Comments: US-GLAXOSMITHKLINE-US2021254948:Same reporter. US-GLAXOSMITHKLINE-US2021254932:Same reporter.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1967080

GLAXOSMITHKLINE BIOLOGICALS · HEP A (HAVRIX) · Charge U95H7

gering
Staat
CO
Alter
1,0
Geschlecht
M
Eingang
21.12.2021
Impfdatum
09.12.2021
Beginn
09.12.2021
Tage bis Beginn
0,0
Dosis
2
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Extra dose administered Incorrect dose administered Product administered to patient of inappropriate age

Symptomtext

This case was reported by a physician via call center representative and described the occurrence of overdose in a 1-year-old male patient who received HAV (Havrix adult) (batch number U95H7, expiry date 22nd May 2022) for prophylaxis. Co-suspect products included HAV (Havrix adult) (batch number U95H7, expiry date unknown) for prophylaxis. Previously administered products included Havrix (1st dose received on an unknown date). On 9th December 2021, the patient received the 3rd dose of Havrix adult. On an unknown date, the patient received the 2nd dose of Havrix adult. On 9th December 2021, unknown after receiving Havrix adult and not applicable after receiving Havrix adult, the patient experienced extra dose administered, adult product administered to child and overdose. On an unknown date, the patient experienced overdose and adult product administered to child. On an unknown date, the outcome of the overdose, adult product administered to child, extra dose administered, adult product administered to child and overdose were unknown. Additional details were provided as follows: The age at vaccination was not reported. Physician reported that the patient received adult dose of the Havrix vaccine inadvertently for his second and third dose of the series, which led to overdose, adult product administered to child and extra dose administered. No further information reported. The reporter consented to follow-up. This case has been linked with cases US2021254949 and US2021254932 reported by the same reporter.; Sender's Comments: US-GLAXOSMITHKLINE-US2021254932:Same reporter. US-GLAXOSMITHKLINE-US2021254949:Same reporter.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1967080

GLAXOSMITHKLINE BIOLOGICALS · HEP A (HAVRIX) · Charge U95H7

gering
Staat
CO
Alter
1,0
Geschlecht
M
Eingang
21.12.2021
Impfdatum
09.12.2021
Beginn
09.12.2021
Tage bis Beginn
0,0
Dosis
3
Route/Site
- / LL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Extra dose administered Incorrect dose administered Product administered to patient of inappropriate age

Symptomtext

This case was reported by a physician via call center representative and described the occurrence of overdose in a 1-year-old male patient who received HAV (Havrix adult) (batch number U95H7, expiry date 22nd May 2022) for prophylaxis. Co-suspect products included HAV (Havrix adult) (batch number U95H7, expiry date unknown) for prophylaxis. Previously administered products included Havrix (1st dose received on an unknown date). On 9th December 2021, the patient received the 3rd dose of Havrix adult. On an unknown date, the patient received the 2nd dose of Havrix adult. On 9th December 2021, unknown after receiving Havrix adult and not applicable after receiving Havrix adult, the patient experienced extra dose administered, adult product administered to child and overdose. On an unknown date, the patient experienced overdose and adult product administered to child. On an unknown date, the outcome of the overdose, adult product administered to child, extra dose administered, adult product administered to child and overdose were unknown. Additional details were provided as follows: The age at vaccination was not reported. Physician reported that the patient received adult dose of the Havrix vaccine inadvertently for his second and third dose of the series, which led to overdose, adult product administered to child and extra dose administered. No further information reported. The reporter consented to follow-up. This case has been linked with cases US2021254949 and US2021254932 reported by the same reporter.; Sender's Comments: US-GLAXOSMITHKLINE-US2021254932:Same reporter. US-GLAXOSMITHKLINE-US2021254949:Same reporter.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1967079

GLAXOSMITHKLINE BIOLOGICALS · HEP A (HAVRIX) · Charge U95H7

gering
Staat
CO
Alter
1,0
Geschlecht
M
Eingang
21.12.2021
Impfdatum
09.12.2021
Beginn
09.12.2021
Tage bis Beginn
0,0
Dosis
2
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Extra dose administered Incorrect dose administered Product administered to patient of inappropriate age

Symptomtext

This case was reported by a physician via call center representative and described the occurrence of overdose in a 1-year-old male patient who received HAV (Havrix adult) (batch number U95H7, expiry date 22nd May 2022) for prophylaxis. Co-suspect products included HAV (Havrix adult) (batch number U95H7, expiry date unknown) for prophylaxis. On 9th December 2021, the patient received the 3rd dose of Havrix adult. On an unknown date, the patient received the 2nd dose of Havrix adult. On 9th December 2021, unknown after receiving Havrix adult and not applicable after receiving Havrix adult, the patient experienced extra dose administered, adult product administered to child and overdose. On an unknown date, the patient experienced overdose and adult product administered to child. On an unknown date, the outcome of the overdose, adult product administered to child, extra dose administered, adult product administered to child and overdose were unknown. Additional details were provided as follows: The physician reported that the patient received adult dose of the Havrix vaccine inadvertently for his second and third dose of the series, which led to overdose, adult product administered to child and extra dose administered. The reporter consented to follow-up. No further information reported. This case had been linked with cases US2021254949 and US2021254948 reported by the same reporter.; Sender's Comments: US-GLAXOSMITHKLINE-US2021254948:Same reporter. US-GLAXOSMITHKLINE-US2021254949:Same reporter.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1967079

GLAXOSMITHKLINE BIOLOGICALS · HEP A (HAVRIX) · Charge U95H7

gering
Staat
CO
Alter
1,0
Geschlecht
M
Eingang
21.12.2021
Impfdatum
09.12.2021
Beginn
09.12.2021
Tage bis Beginn
0,0
Dosis
3
Route/Site
- / LL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Extra dose administered Incorrect dose administered Product administered to patient of inappropriate age

Symptomtext

This case was reported by a physician via call center representative and described the occurrence of overdose in a 1-year-old male patient who received HAV (Havrix adult) (batch number U95H7, expiry date 22nd May 2022) for prophylaxis. Co-suspect products included HAV (Havrix adult) (batch number U95H7, expiry date unknown) for prophylaxis. On 9th December 2021, the patient received the 3rd dose of Havrix adult. On an unknown date, the patient received the 2nd dose of Havrix adult. On 9th December 2021, unknown after receiving Havrix adult and not applicable after receiving Havrix adult, the patient experienced extra dose administered, adult product administered to child and overdose. On an unknown date, the patient experienced overdose and adult product administered to child. On an unknown date, the outcome of the overdose, adult product administered to child, extra dose administered, adult product administered to child and overdose were unknown. Additional details were provided as follows: The physician reported that the patient received adult dose of the Havrix vaccine inadvertently for his second and third dose of the series, which led to overdose, adult product administered to child and extra dose administered. The reporter consented to follow-up. No further information reported. This case had been linked with cases US2021254949 and US2021254948 reported by the same reporter.; Sender's Comments: US-GLAXOSMITHKLINE-US2021254948:Same reporter. US-GLAXOSMITHKLINE-US2021254949:Same reporter.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-